XPhyto Therapeutics Corp.
15.12.2021 09:06:53 CET | ACCESS Newswire | Press release
VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / December 15, 2021 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide an update on the development of its fast-dissolving CBD oral strips. With significant complexities involved in the planning and preparation for the pending human pilot study, the Company is pleased to announce that its European human CBD bioavailability study will commence in January 2022.
Prof. Dr. Beckert said, "the clinical trial of our CBD product is aiming to demonstrate the efficient and precise dosing of the treatment. If successful, this could make a significant difference to Epilepsy patients and we are excited to commence the trial next year."
XPhyto is developing a hybrid-generic CBD prescription drug formulation that employs the Company's proprietary oral dissolvable ("ODF") platform to deliver precise and efficient CBD dosages for the treatment of certain forms of childhood Epilepsy.
The US Food & Drug Administration (FDA) and European Medicines Agency (EMA) have approved CBD based medical products from other companies for the treatment of severe childhood forms of Epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome. The currently approved and registered formulation of CBD is a lipophilic solution in sesame oil with a standard dosage of 750 mg/day. Due to low bioavailability (approximately 5%) the formulation could be considered highly inefficient compared to the XPhyto ODF platform.
For the purpose of carrying out XPhyto's clinical study, the following important and necessary items have been completed or received: Product Development Report, Investigational Medicinal Product Dossier, Permit for Clinical Study, manufacture of clinical product samples; Product Specification File; monitoring agreement; and Import Authorization to the location of the FDA-inspected Clinical Research Center. Pending success in the CBD pilot study, the Company expects to carry out a pivotal clinical study in 2H of 2022.
The Company's CBD-based Epilepsy treatment program is one of several dissolvable oral drug delivery programs. Oral thin film drug delivery is a large and growing international industry which provides an alternative to conventional solid and liquid oral dosage forms. Transparency Market Research estimates that the global market for thin film drug manufacturing will be worth US$15.98 billion by 2024, rising at a 9.0% CAGR between 2019 and 2024. XPhyto's additional oral thin film drug delivery programs include both cannabinoid and non-cannabinoid products for pain, neurology, and infectious disease. The Cannabidiol Market revenue is estimated to be worth over US$89 billion by 2026 according to Global Market Insights Inc.
Executive management of XPhyto's drug formulation business is led by Prof. Dr. Beckert, managing director of Vektor Pharma TF GmbH. Prof Dr. Beckert is a German-based scientist and experienced corporate executive who is leading XPhyto's drug formulation and diagnostics operations.
About XPhyto Therapeutics Corp.
XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
XPhyto Therapeutics Corp.
Hugh Rogers, CEO and Director
Investor Inquiries:
Mr. Knox Henderson
T: 604-551-2360
E: info@xphyto.com
Forward looking statements
This news release includes statements containing forward-looking information within the meaning of applicable Canadian securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "develop", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "potential", "propose" and other similar words, or statements that certain events or conditions "may" or "will" occur, and in this release include the statement regarding the Company's goal of building a successful diagnostic, drug delivery, and medical cannabis company. Forward-looking statements are only predictions based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements, including: that the Company may not succeed in developing a commercial product; that the sale of products may not be a viable business; that the Company may be unable to scale its business; product liability risks; product regulatory risk; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; currency risks; competition; international risks; and other risks beyond the Company's control. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this news release.
SOURCE: XPhyto Therapeutics Corp.
View source version on accesswire.com:
https://www.accesswire.com/677717/XPhyto-Epilepsy-Clinical-Trial-Planned-in-2022-with-Its-Proprietary-Fast-Dissolving-CBD-Oral-Strips
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Synexis and Customate Collaborate to Advance Continuous Indoor Pathogen Control for the U.K. Poultry Industry5.10.2026 22:10:00 CEST | Press release
OVERLAND PARK, KS AND YORKSHIRE, ENGLAND / ACCESS Newswire / October 5, 2026 / Synexis®, LLC, the leader in touchless, continuous pathogen control technology, has announced a strategic collaboration with Customate Solutions, a family-owned engineering company and trusted provider of innovative manufacturing solutions with deep expertise across the poultry industry. The collaboration will bring Synexis patented DHP® technology to poultry producers throughout the United Kingdom and Ireland, helping hatcheries, poultry farms, processing facilities, and related operations strengthen indoor pathogen control while supporting modern biosecurity strategies. Poultry producers today face increasing pressure to maximize healthy hatch rates, improve chick quality, and strengthen biosecurity while reducing operational risk. Bacterial contamination on hatching eggs and throughout hatchery environments can directly impact hatchability, flock health, and production performance, making effective pathog
Chervon Names Claudio Chiappetta Vice President of Retail Sales for Chervon Canada5.10.2026 14:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 5, 2026 / Claudio Chiappetta joins Chervon as Vice President of Retail Sales for Chervon Canada; effective Monday, October 5, 2026, reporting to VP, MD Neil Harrison. A graduate of York University in Toronto, Chiappetta majored in business and marketing. He brings over 25 years of outdoor power equipment and power tool experience to Chervon as well as extensive knowledge of the Canadian home improvement and outdoor power equipment markets. Chiappetta launched his tool and outdoor career in 2003 at Black & Decker/DeWalt where he held various sales and marketing positions including cordless product manager for DeWalt Power Tools. Claudio joined TTI Milwaukee in 2008 where he was responsible for the launch of a series of Milwaukee cordless products into the Canadian market. He went on to build and manage the Ryobi outdoor power equipment portfolio along with multiple TTI power tool brands. "I am delighted to welcome Claudio to our Canadian senior
Chervon Names Daniel L. Abbott Director of Sales - Western U.S.A.5.10.2026 14:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 5, 2026 / Daniel L. Abbott joins Chervon as Director of Sales - Western U.S.A.; effective Monday, October 5, 2026, reporting to SVP Matt DeFeo. Abbott brings over 30 years of experience in the power tool, outdoor power equipment, and home improvement industry. As a graduate of Long Beach State, Abbott went on to serve for 4 years in the United States Airforce. Abbott then moved on to become a Home Depot Store Manager in Huntington Beach, California. Abbott then joined TTI/Milwaukee where he spent 24 years building, managing and leading an elite west coast-based sales team. Abbott was promoted through increasingly responsible positions until his final role as sales leader of over 700 salespeople. "Abbott is a proven and exceptional leader and mentor of high-potential sales talent," says SVP Matt DeFeo. "His obsessive focus on teaming up with key accounts at the store level has unleashed years of extraordinary growth in his areas of responsibili
Securitas Technology Releases 2027 Global Technology Outlook Report5.10.2026 14:00:00 CEST | Press release
UNIONTOWN, OH / ACCESS Newswire / October 5, 2026 / Securitas Technology, one of the world's largest electronic security companies, today announced the release of its 2027 Global Technology Outlook Report, offering organizations practical insights into the technologies, trends, and business priorities transforming the electronic security industry. Highly anticipated by security professionals across the globe - and now in its ninth annual edition - the Global Technology Outlook Report brings together perspectives from more than 16,000 end-user clients across 19 countries, independent research with more than 575 security decision-makers, 26 of the world's leading manufacturers, innovators, and Securitas Technology subject matter experts from around the world. The result is the industry's most comprehensive view of how security programs are evolving to address growing complexity, emerging risks, and rapidly changing technology. As security increasingly supports business resilience, operat
Chervon Names Peter J. Carlson Director of Sales for Strategic Accounts5.10.2026 14:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 5, 2026 / Peter J. Carlson joins Chervon as Director of Sales for Strategic Accounts effective Monday, October 5, 2026, reporting to SVP of Industrial and Commercial Sales, Jeff Campbell. Carlson brings over 27 years of power tool and outdoor product key account management experience to Chervon. A graduate of Bemidji State University in Bemidji, Minnesota; Carlson launched his career at Makita Power Tools in 1999. He progressed through a series of positions at Makita over the subsequent 10 years. In 2009, Carlson joined TTI/Milwaukee as a Senior National Account Manager. His career flourished as he was promoted through a series of increasingly responsible positions building and managing strategic key account business for TTI/Milwaukee. "Carlson is highly regarded in his ability to not only build the business but also to mentor, train and develop his people," SVP Campbell said. "His extensive experience at building store level and E-Commerce gr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom